What question did this study set out to answer?

The aim is to investigate the role of SETD8 in ovarian clear cell carcinoma and its effects on RNA metabolism.

April 18, 2026Open Access

SETD8 promotes ovarian clear cell carcinoma by epigenetically activating RNA metabolism genes via H4K20me1

Key Points

The aim is to investigate the role of SETD8 in ovarian clear cell carcinoma and its effects on RNA metabolism.
Utilized integrative ChIP-seq and RNA-seq analyses in ovarian clear cell carcinoma cells.
Applied pharmacological inhibition and RNA interference for SETD8 depletion.
Conducted transcriptomic profiling to assess gene expression changes.
Analyzed clinical data from public datasets to evaluate SETD8 expression and survival correlation.
SETD8 maintains expression of critical RNA processing genes independent of p53.
Inhibition of SETD8 leads to reduced global H4K20me1 levels and impaired cellular proliferation.
Increased lipid peroxidation consistent with ferroptotic stress observed upon SETD8 depletion.
High SETD8 expression correlates with poor overall survival in clear cell lineage tumors.

Abstract

Ovarian clear cell carcinoma (OCCC) is a chemoresistant subtype of epithelial ovarian cancer with limited therapeutic options and distinct molecular features. Histone methyltransferase SETD8 catalyzes the monomethylation of histone H4 at lysine 20 (H4K20me1) and has been implicated in transcriptional regulation across multiple cancer types. In endometrial cancer, we previously demonstrated that SETD8 regulates downstream targets through integrative ChIP-seq and RNA-seq analyses, linking its activity to p53-dependent signaling pathways. However, the role of SETD8 in OCCC and its potential tumor-context–specific functions remain undefined. Integrative analyses of ChIP-seq and RNA-seq in OCCC revealed that SETD8 maintains the expression of genes critical for RNA processing, including HNRNPA2B1, EIF4G1, and SRSF3, in a manner independent of p53 signaling. Pharmacological inhibition or RNA interference–mediated depletion of SETD8 resulted in a pronounced reduction of global H4K20me1 levels, impaired cellular proliferation, and increased lipid peroxidation consistent with ferroptotic stress. Transcriptomic profiling further demonstrated that SETD8 inhibition reprograms ferroptosis-associated gene expression, establishing a mechanistic link between chromatin-based transcriptional control and cellular redox vulnerability. Furthermore, clinical data analysis from public datasets (GSE29450 and TCGA-KIRC) confirmed that SETD8 is significantly overexpressed in OCCC tissues compared to normal counterparts and that high SETD8 expression correlates with poor overall survival in clear cell lineage tumors, underscoring its potential as a clinical biomarker. Our study provides an in vitro mechanistic framework in which SETD8 safeguards RNA metabolic integrity and mitigates ferroptotic stress through epigenetic regulation in OCCC. These results underscore the lineage-specific roles of SETD8 across gynecologic malignancies and identify SETD8 as a potential therapeutic vulnerability that warrants further in vivo investigation.

Bookmark

View Full Paper